Endostatin gene therapy inhibits intratumoral macrophage M2 polarization
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1016/j.biopha.2016.01.035 https://repositorio.unifesp.br/handle/11600/56147 |
Resumo: | Background: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved. |
id |
UFSP_f5dacae35d20b47bdc848221b4936cf4 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/56147 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarizationRenal cell carcinomaEndostatinTumor-associated macrophagesBackground: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved.Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, BrazilIPEN CNEN, Dept Biotechnol, Sao Paulo, BrazilUniv Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Biol Biol Sci, Sao Paulo, BrazilUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Biol Biol Sci, Sao Paulo, BrazilWeb of ScienceFAPESPCNPqCAPES/PNPDFAPESP: 2011/18703-2CNPq: 473102/2012-9Elsevier France-Editions Scientifiques Medicales Elsevier2020-07-22T13:23:17Z2020-07-22T13:23:17Z2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion102-111application/pdfhttp://dx.doi.org/10.1016/j.biopha.2016.01.035Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016.10.1016/j.biopha.2016.01.035WOS000373527100014.pdf0753-3322https://repositorio.unifesp.br/handle/11600/56147WOS:000373527100014engBiomedicine & PharmacotherapyParisinfo:eu-repo/semantics/openAccessFoguer, Karen [UNIFESP]Braga, Marina de Souza [UNIFESP]Schatzmann Peron, Jean PierreBortoluci, Karina Ramalho [UNIFESP]Bellini, Maria Helena [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-11T10:25:00Zoai:repositorio.unifesp.br/:11600/56147Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-11T10:25Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
title |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
spellingShingle |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization Foguer, Karen [UNIFESP] Renal cell carcinoma Endostatin Tumor-associated macrophages |
title_short |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
title_full |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
title_fullStr |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
title_full_unstemmed |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
title_sort |
Endostatin gene therapy inhibits intratumoral macrophage M2 polarization |
author |
Foguer, Karen [UNIFESP] |
author_facet |
Foguer, Karen [UNIFESP] Braga, Marina de Souza [UNIFESP] Schatzmann Peron, Jean Pierre Bortoluci, Karina Ramalho [UNIFESP] Bellini, Maria Helena [UNIFESP] |
author_role |
author |
author2 |
Braga, Marina de Souza [UNIFESP] Schatzmann Peron, Jean Pierre Bortoluci, Karina Ramalho [UNIFESP] Bellini, Maria Helena [UNIFESP] |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Foguer, Karen [UNIFESP] Braga, Marina de Souza [UNIFESP] Schatzmann Peron, Jean Pierre Bortoluci, Karina Ramalho [UNIFESP] Bellini, Maria Helena [UNIFESP] |
dc.subject.por.fl_str_mv |
Renal cell carcinoma Endostatin Tumor-associated macrophages |
topic |
Renal cell carcinoma Endostatin Tumor-associated macrophages |
description |
Background: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we investigated the impact of ES gene therapy on the polarization of tumor-associated macrophages (TAMs) in lung metastases from tumor-bearing mice. Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used to analyze plasma and cell culture supernatant cytokines. Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines, including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1, declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 + CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the culture supernatants of the ES-treated group. Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role. However, aside from promoting interferon-g secretion and an effective T cell response, we show here that this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and thus favoring tumor elimination. (C) 2016 Elsevier Masson SAS. All rights reserved. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 2020-07-22T13:23:17Z 2020-07-22T13:23:17Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.biopha.2016.01.035 Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016. 10.1016/j.biopha.2016.01.035 WOS000373527100014.pdf 0753-3322 https://repositorio.unifesp.br/handle/11600/56147 WOS:000373527100014 |
url |
http://dx.doi.org/10.1016/j.biopha.2016.01.035 https://repositorio.unifesp.br/handle/11600/56147 |
identifier_str_mv |
Biomedicine & Pharmacotherapy. Paris, v. 79, p. 102-111, 2016. 10.1016/j.biopha.2016.01.035 WOS000373527100014.pdf 0753-3322 WOS:000373527100014 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Biomedicine & Pharmacotherapy |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
102-111 application/pdf |
dc.coverage.none.fl_str_mv |
Paris |
dc.publisher.none.fl_str_mv |
Elsevier France-Editions Scientifiques Medicales Elsevier |
publisher.none.fl_str_mv |
Elsevier France-Editions Scientifiques Medicales Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268389364858880 |